天康生物
(002100)
| 流通市值：115.50亿 | | | 总市值：115.50亿 |
| 流通股本：13.65亿 | | | 总股本：13.65亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 12,817,072,887.91 | 8,325,389,560.74 | 3,916,826,741.94 | 16,981,074,699.26 |
| 营业总成本 | 13,458,921,013.01 | 8,784,305,956.8 | 4,059,490,050.25 | 16,576,749,906.39 |
| 其他经营收益 | | | | |
| 营业利润 | -641,205,419.13 | -471,166,232.74 | -154,989,363.3 | 322,209,571.62 |
| 利润总额 | -650,356,638.48 | -488,911,179.55 | -163,688,307.21 | 328,109,399.22 |
| 净利润 | -652,611,934.69 | -494,200,330.27 | -172,508,165.96 | 300,308,190.47 |
| 每股收益 | | | | |
| 其他综合收益 | 115,008,838.55 | -52,668,595.28 | 77,495,593.39 | 13,946,007.7 |
| 综合收益总额 | -537,603,096.14 | -546,868,925.55 | -95,012,572.57 | 314,254,198.17 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 9,985,599,169.22 | 8,960,020,321.98 | 10,789,449,984.81 | 9,949,972,555.7 |
| 非流动资产: | | | | |
| 非流动资产合计 | 10,109,872,872.64 | 10,220,180,753.92 | 7,253,811,412.74 | 7,441,222,454.02 |
| 资产总计 | 20,095,472,041.86 | 19,180,201,075.9 | 18,043,261,397.55 | 17,391,195,009.72 |
| 流动负债: | | | | |
| 流动负债合计 | 7,549,706,002.61 | 6,856,589,495.33 | 6,603,728,107.98 | 6,494,788,633.18 |
| 非流动负债: | | | | |
| 非流动负债合计 | 3,950,200,595.96 | 3,799,545,372.95 | 2,997,826,203.74 | 2,359,686,036.02 |
| 负债合计 | 11,499,906,598.57 | 10,656,134,868.28 | 9,601,554,311.72 | 8,854,474,669.2 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 6,379,204,663.17 | 6,342,155,835.48 | 6,858,967,727.17 | 6,941,275,931.63 |
| 股东权益合计 | 8,595,565,443.29 | 8,524,066,207.62 | 8,441,707,085.83 | 8,536,720,340.52 |
| 负债和股东权益合计 | 20,095,472,041.86 | 19,180,201,075.9 | 18,043,261,397.55 | 17,391,195,009.72 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 12,685,114,119.79 | 8,235,226,885.62 | 4,176,903,967.89 | 18,188,368,519.62 |
| 经营活动现金流出小计 | 12,283,447,260.44 | 6,739,272,899.97 | 3,445,532,234.15 | 17,807,506,779.69 |
| 经营活动产生的现金流量净额 | 401,666,859.35 | 1,495,953,985.65 | 731,371,733.74 | 380,861,739.93 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,168,929,159.92 | 264,929,159.92 | 264,656,811.64 | 371,453,904.98 |
| 投资活动现金流出小计 | 2,026,163,253.69 | 718,045,714.62 | 180,668,974.73 | 1,658,901,069.51 |
| 投资活动产生的现金流量净额 | -857,234,093.77 | -453,116,554.7 | 83,987,836.91 | -1,287,447,164.53 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 5,849,882,700 | 2,698,915,800 | 1,450,000,000 | 5,366,359,410.22 |
| 筹资活动现金流出小计 | 4,470,221,528.5 | 3,011,874,883.41 | 1,223,867,140.99 | 6,002,460,516.03 |
| 筹资活动产生的现金流量净额 | 1,379,661,171.5 | -312,959,083.41 | 226,132,859.01 | -636,101,105.81 |
| 汇率变动对现金及现金等价物的影响 | - | - | - | -47,027.52 |
| 现金及现金等价物净增加额 | 924,093,937.08 | 729,878,347.54 | 1,041,492,429.66 | -1,542,733,557.93 |
| 期末现金及现金等价物余额 | 2,334,922,929.05 | 2,140,707,339.51 | 2,452,321,421.63 | 1,410,828,991.97 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 729,878,347.54 | - | -1,542,733,557.93 |
最新报告期：2026-11-04| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 国信证券 | 李瑞楠,江海航,鲁家瑞 | -0.55 | 0.26 | 0.59 | 2026-11-04 |
| 太平洋 | 程晓东 | -0.25 | 0.59 | 0.73 | 2026-10-30 |
| 开源证券 | 陈雪丽 | -0.32 | 0.55 | 0.83 | 2026-10-28 |
| 浙商证券 | 张心怡,钟凯锋 | -0.14 | 0.55 | 0.62 | 2026-09-08 |
| 开源证券 | 陈雪丽 | -0.23 | 0.55 | 0.84 | 2026-09-04 |